In order to obtain special lactic acid bacteria with potent uric acid-lowering activity, this study screened lactic acid bacterial strains for their ability to degrade inosine and guanosine by high performance liquid chromatography (HPLC). The strain LB1lac20 was found to give the highest degradation rate of inosine (91.19%) and guanosine (89.67%). By sequence alignment of 16S rRNA gene using the Basic Local Alignment Search Tool (BLAST), LB1lac20 was identified as Lactobacillus brevis. To evaluate its uric acid-lowering potential, an in vitro model was established by the uric acid production method and used to analyze the inhibitory effect of LB1lac20 on xanthine oxidase. The results showed that the activity of xanthine oxidase was 21.27% and 19.60% inhibited by the live suspension and intracellular extract of LB1lac20, respectively (P < 0.05). To sum up, L. brevis LB1lac20 may set the stage for the development of drugs for the prevention and treatment of hyperuricemia.